Renovia, medtech startup founded partly by Marc Beer, is going to focus on putting many new products for pelvic floor disorders.
This new focus comes after finishing a Series B Round that cost $32 million and raking up $40 millionw in venture debt.
This company headquartered in Boston is working on different kinds of therapeutic and diagnostic products to deal with pelvic floor disorders like urinary incontinence. These pelvic disorders are believed by researchers about 250 million women in the world. The first pelvic product by Renovia to be FDA-approved was a product called Leva.
To help pay fo the Series B roud, Renovia got financial help from the hi e al t h c ar e – f cused firm called Longwood Fund to help finish the Series B round. Perceptive Advisors and Ascension Ventures also helped make success in the Series B round possible. This financial help from these companies will enable Renovia to make and rest four new diagnoisstic and therapeutic products, including a new version of the Leva device.
Beer is happy to have the help of leading healthcare investors who agree on how they should improve, trat and diagnose millions of women that are being affected by pelvic disorders. He believes that his company can combine proprietary and innovative sensor technologies with a virtual health platform is a good way for customers to get data about new treatment choices. The data should also help them understand pelvic disorders and hopefully lower how much women pay for the products.a
Marc Beer is also the chairman and co-founder of Renovia. To these positions, he brings about 25 years of experience in developing and commercializing pharmaceuticals, biotechnology, diagnostics and devices. Ramon Iglesias, MD and Yolanda Lorie are also founders of Renovia.
Before Renovia, he was the CEO of other pharmaceuticals companies. One of these companies was dedicated to develping and doing innovative therapies for people who have debilitating rare diseases. He was able to take one of these companies public and was able to get lomitapide approved by the American FDA to treat homozygous familial hypercholesterolemia. This drug was able to get approved in 38 countries.
Learn more: https://www.slideshare.net/MarcBeer